The new crown pandemic continues to rage all over the world, with the number of new confirmed cases in a single day approaching the record high, and the control of the pandemic has encountered unprecedented challenges.
At this critical moment, the new crown vaccines of the two adenovirus recombinant vectors of AstraZeneca and Johnson & Johnson have been exposed to the side effects of the deadly brain venous thrombosis (CVT), which has made the epidemic control crisis even worse.
Since the two vaccines involved are both adenovirus recombinant vector vaccines, many people blame the side effects of the vaccine on the technical lines of the production of adenovirus recombinant vaccines.
At the same time, two mRNA vaccine companies have also issued statements one after another, leaving their vaccines out of no way to have any connection with this fatal side effect.
However, the author has pointed out earlier that given the fact that the risk of thrombosis in patients with new coronavirus infection has increased significantly, it may be "guessed" that the risk of thrombosis is originally a complication inherent in the new coronavirus infection and the new coronavirus vaccine (regardless of the technical line).
results found that the risk of CVT in the new coronavirus infection is about 100 times higher than that in the general population, and nearly 10 times higher than that after the new coronavirus vaccination.
Importantly, there is no significant difference in the risk of this fatal effect compared to the two mRNA vaccines.
This means that, as the author "guesses", this thrombosis risk may be an inherent complication of the new coronavirus infection or vaccine.
Researchers from Oxford evaluated the absolute incidence of (PVT) 4 portal venous thrombosis (CVT) and portal venous thrombosis (PVT) recorded in electronic medical records.
Results: The incidence of CVT within 2 weeks of confirmed COVID-19 infection was 39.0 cases per million people, significantly higher than 0.0 cases per million people with influenza, or 4.1 cases per million people with two mRNA vaccines.
At the same time, the incidence of CVT within 2 weeks of COVID-19 infection was also significantly higher than the 5.0 cases per million people who received the AstraZeneca COVID-19 vaccine announced by the European Medicines Agency (EMA); the historical incidence of 0.41 people per million population in the general population in any two weeks, and 0.53 to 0.77 cases per million people in any two weeks in the United States.
This means that the risk of CVT within 2 weeks of COVID-19 infection is about 100 times higher than that of the general population, and about 8 to 10 times higher than that of the new crown vaccination.
The total risk of 5 CVT per million people after AstraZeneca vaccination is not significantly different from the risk of CVT per million people within 2 weeks after the two mRNA vaccination.
If CVT is replaced with portal venous thrombosis (PVT), the absolute incidence rate of COVID-19 infection within two weeks is 436.4 cases per million people, significantly higher than 98.4 cases per million people after receiving influenza vaccination, or 44.9 cases per million people after receiving mRNA vaccination;
The risk of PVT in two weeks of COVID-19 infection is significantly higher than the EMA report on visceral thrombosis per million people after receiving AstraZeneca COVID-19 vaccine (53 of 34 million people).
At the same time, the risk of PVT after receiving two mRNA vaccines is 10 times that of the AstraZeneca vaccine data released by EMA.
report further pointed out that if CVT is replaced with G08 representing intracranial and spinal canal phlebitis and thrombophlebitis in the International Disease Code (ICD-10), the incidence rate reached 171.4 cases per million people within two weeks after the infection of the new coronavirus, significantly higher than 52.1 cases per million people after the diagnosis of influenza, or 22.7 cases per million after receiving mRNA vaccine.
In short, this report from the University of Oxford shows that although rare, the risk of venous thrombosis is significantly higher than that of the general population, whether infected with the new coronavirus or vaccinated with AstraZeneca or mRNA COVID-19 vaccine.
Of course, the risk of getting infected with the new coronavirus is much higher.
From the perspective of risk/return trade-off, vaccination is imperative in the face of the more rampant COVID-19 pandemic, even if there is a risk of such fatal side effects.
